<DOC>
	<DOCNO>NCT01428063</DOCNO>
	<brief_summary>The purpose study provide anti-hepatitis C virus drug patient receive placebo + peginterferon alfa-2a + ribavirin prior Bristol-Myers Squibb ( BMS ) study determine whether addition drug result high cure rate patient previously fail therapy . Approximately 100 genotype 1b patient receive placebo BMS study NCT01428063 ( AI447-028 ) receive active drug study .</brief_summary>
	<brief_title>Study pegInterferon Alfa-2a , Ribavirin , Daclatasvir ( BMS-790052 ) With Without BMS-650032 Participants Some Hepatitis C Virus Trials</brief_title>
	<detailed_description>- Intervention Model : - Parallel : patient enter trial - Cross-over : genotype 1b patient roll NCT01428063 ( AI447-028 ) require rescue therapy initial treatment study - Peginterferon alfa-2a - Ribavirin - Daclatasvir - Asunaprevir</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<mesh_term>Interferon-alpha</mesh_term>
	<mesh_term>Peginterferon alfa-2a</mesh_term>
	<criteria>Key Prior participation BMS790052 , BMS650032 , BMS791325 trial assign control arm ( pegIFNα2a/ribavirin + placebo ) trial Hepatitis C virus ( HCV ) genotype 1 , 2 , 3 , 4 ( mixed genotype permit ) HCV RNA viral load detectable Key Discontinuation prior BMS HCV clinical trial due pegIFNα2a/ribavirinrelated event Any antiHCV therapy follow initial treatment BMS650032 , BMS790052 , BMS791325 Positive hepatitis B infection ( hepatitis B surface antigen ) HIV1 HIV2 antibody screen Evidence medical condition associate chronic liver disease HCV infection Evidence decompensated cirrhosis base radiologic criterion biopsy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>